Co-Diagnostics (CODX) Misses Q2 EPS by 16c

Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of $0.43, $0.16 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $24.04 million versus the consensus estimate of $26.45 million.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)